Photopharmica was established in 2001 to develop novel photosensitisers as products for medical use. The Company has opened up new applications of topical photodynamic therapy and produced photosensitisers that have improved properties compared with those previously available. This has been achieved by harnessing IP and expertise from more than 15 years research from the University of Leeds and the company’s R&D, which includes collaboration with high profile Universities including: Harvard, Toronto, Manchester, Dundee and Leeds. The Company has been conducting clinical trials since 2004 and further trials are planned. Photopharmica has just completed a successful phase IIb repeat dose chronic leg ulcer trial which reported during Q3 2011.

The Company strategy is to discover and acquire novel photosensitiser based technology and develop the technology through phase II clinical trials. Later clinical development, regulatory approval and marketing will be achieved by licensing or co-development agreements and appropriate partners. The Company has positioned itself so as to be able to respond to the needs of partners to develop its products both as devices and as pharmaceuticals.

The Company has a number of collaborations and encourages approaches from prospective partners who hold a significant position within their own market.